[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100345244":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":17,"locations":7,"responsibleParty":23,"collaborators":7,"id":25,"slug":7,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":7,"acronym":7,"eligibilityCriteria":29,"healthyVolunteers":26,"sex":30,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":31,"phases":7,"briefSummary":32,"conditions":33,"keywords":37,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"Ultragenyx Pharmaceutical Inc","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":12},"DRUG","Mepsevii",[13,14,15,16],"UX003","recombinant human beta-glucuronidase","rhGUS","vestronidase alfa",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Early Access","CONTACT","1-415-483-8800","EarlyAccess@ultragenyx.com",{"type":24,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100345244",false,"NCT03775174","Expanded Access to Mepsevii","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","ALL","EXPANDED_ACCESS","Individual patient expanded access requests may be considered for patients who have no other treatment options",[34,35,36],"MPS VII","Mucopolysaccharidosis VII","Sly Syndrome",[38,39],"Expanded Access","Compassionate Use","AVAILABLE","2026-04-06",{"date":43,"type":44},"2026-04-07","ACTUAL",{"name":5,"class":6}]